JP2022531388A5 - - Google Patents

Info

Publication number
JP2022531388A5
JP2022531388A5 JP2021564995A JP2021564995A JP2022531388A5 JP 2022531388 A5 JP2022531388 A5 JP 2022531388A5 JP 2021564995 A JP2021564995 A JP 2021564995A JP 2021564995 A JP2021564995 A JP 2021564995A JP 2022531388 A5 JP2022531388 A5 JP 2022531388A5
Authority
JP
Japan
Application number
JP2021564995A
Other languages
Japanese (ja)
Other versions
JPWO2020227101A5 (https=
JP7667573B2 (ja
JP2022531388A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/031046 external-priority patent/WO2020227101A1/en
Publication of JP2022531388A publication Critical patent/JP2022531388A/ja
Publication of JPWO2020227101A5 publication Critical patent/JPWO2020227101A5/ja
Publication of JP2022531388A5 publication Critical patent/JP2022531388A5/ja
Priority to JP2025062493A priority Critical patent/JP2025102975A/ja
Application granted granted Critical
Publication of JP7667573B2 publication Critical patent/JP7667573B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021564995A 2019-05-03 2020-05-01 Kcnt1阻害剤および使用する方法 Active JP7667573B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025062493A JP2025102975A (ja) 2019-05-03 2025-04-04 Kcnt1阻害剤および使用する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962842849P 2019-05-03 2019-05-03
US62/842,849 2019-05-03
US202062982864P 2020-02-28 2020-02-28
US62/982,864 2020-02-28
PCT/US2020/031046 WO2020227101A1 (en) 2019-05-03 2020-05-01 Kcnt1 inhibitors and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025062493A Division JP2025102975A (ja) 2019-05-03 2025-04-04 Kcnt1阻害剤および使用する方法

Publications (4)

Publication Number Publication Date
JP2022531388A JP2022531388A (ja) 2022-07-06
JPWO2020227101A5 JPWO2020227101A5 (https=) 2023-05-11
JP2022531388A5 true JP2022531388A5 (https=) 2023-05-11
JP7667573B2 JP7667573B2 (ja) 2025-04-23

Family

ID=73051241

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021564995A Active JP7667573B2 (ja) 2019-05-03 2020-05-01 Kcnt1阻害剤および使用する方法
JP2025062493A Pending JP2025102975A (ja) 2019-05-03 2025-04-04 Kcnt1阻害剤および使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025062493A Pending JP2025102975A (ja) 2019-05-03 2025-04-04 Kcnt1阻害剤および使用する方法

Country Status (17)

Country Link
US (1) US20220259193A1 (https=)
EP (1) EP3962481A4 (https=)
JP (2) JP7667573B2 (https=)
KR (1) KR20220016086A (https=)
CN (2) CN114269340A (https=)
AU (1) AU2020267356B2 (https=)
BR (1) BR112021022067A2 (https=)
CA (1) CA3139063A1 (https=)
CL (2) CL2021002877A1 (https=)
CO (1) CO2021016471A2 (https=)
EC (1) ECSP21087884A (https=)
IL (1) IL287768A (https=)
MX (1) MX2021013421A (https=)
PE (1) PE20220016A1 (https=)
SA (1) SA521430751B1 (https=)
SG (1) SG11202112158YA (https=)
WO (1) WO2020227101A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12590083B2 (en) 2019-01-25 2026-03-31 University Of Virginia Patent Foundation Inhibitors of spinster homolog 2 (SPNS2) for use in therapy
KR20250172745A (ko) * 2019-05-03 2025-12-09 프락시스 프리시젼 메디신즈, 인크. Kcnt1 억제제 및 사용 방법
JP7699836B2 (ja) * 2020-02-28 2025-06-30 プラクシス プレシジョン メディシンズ, インコーポレイテッド Kcnt1阻害剤、および使用方法
EP4210824A1 (en) * 2020-09-09 2023-07-19 University of Virginia Patent Foundation Inhibitors of spinster homolog 2 (spns2) for use in therapy
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
TW202227424A (zh) * 2020-11-27 2022-07-16 大陸商瑞石生物醫藥有限公司 芳基或雜芳基取代5員芳雜環化合物及其用途
WO2022140547A2 (en) * 2020-12-22 2022-06-30 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2022231872A1 (en) * 2021-04-29 2022-11-03 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
EP4329735B1 (en) * 2021-04-29 2026-02-25 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2023211850A1 (en) * 2022-04-25 2023-11-02 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use
US20250360117A1 (en) * 2022-06-08 2025-11-27 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use
CN116813505B (zh) * 2023-06-29 2025-09-02 爱斯特(成都)生物制药股份有限公司 一种制备o-甲基-n-苄氧羰基-l-高丝氨酸的方法
WO2025117662A1 (en) * 2023-11-29 2025-06-05 Actio Biosciences, Inc. Heterocyclic compounds useful as kcnt1 inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
TW200301698A (en) * 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
JP2005060255A (ja) * 2003-08-20 2005-03-10 Nippon Nohyaku Co Ltd カルボキサミド類及びこれを有効成分とする有害生物防除剤
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
EP2044061A2 (en) * 2006-07-20 2009-04-08 Mehmet Kahraman Benzothiophene inhibitors of rho kinase
EP2970240B1 (en) 2013-03-14 2018-01-10 Novartis AG 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
ES2895174T3 (es) 2014-09-29 2022-02-17 Scripps Research Inst Moduladores del receptor de esfingosina-1-fosfato para el tratamiento de trastornos cardiopulmonares
EP3275440B1 (en) * 2015-03-25 2022-05-04 National Center for Geriatrics and Gerontology Novel oxadiazole derivative and pharmaceutical containing same
JPWO2017170826A1 (ja) * 2016-03-30 2019-02-14 味の素株式会社 グルカゴン様ペプチド−1受容体作用増強活性を有する化合物
WO2018187480A1 (en) * 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use
JP7699836B2 (ja) * 2020-02-28 2025-06-30 プラクシス プレシジョン メディシンズ, インコーポレイテッド Kcnt1阻害剤、および使用方法
KR20230005168A (ko) * 2020-03-23 2023-01-09 프락시스 프리시젼 메디신즈, 인크. Kcnt1 억제제 및 사용 방법
CA3188825A1 (en) * 2020-07-06 2022-01-13 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
US11773088B2 (en) * 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
WO2022140547A2 (en) * 2020-12-22 2022-06-30 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
EP4329735B1 (en) * 2021-04-29 2026-02-25 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
JP2022531388A5 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)